Skip to main content

ResMed| balance sheet

  • RMD · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$239.53+0.27%Close 13 Nov 2026 · Market value $33.91B

At the end of fiscal 2026 (the year to 30 Jun 2026), ResMed| reported total assets of $8.97B, $1.47B in cash and equivalents, $825.9M of total debt; shareholders' equity was $6.59B.

From ResMed|'s annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 30 Jun 2026.

Annual

ResMed| balance sheet, annual
USDFY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Cash and equivalents$415.6M$488.8M$735.3M$809.5M$876.0M$905.7M$717.2M$731.4M$821.9M$188.7M$147.1M$463.2M$295.3M$273.7M$227.9M$238.4M$1.21B$1.47B
Cash and short-term investments$415.6M$488.8M$735.3M$809.5M$876.0M$905.7M$717.2M$731.4M$821.9M$188.7M$147.1M$463.2M$295.3M$273.7M$227.9M$238.4M$1.21B$1.47B
Accounts receivable————$318.3M$359.6M$362.6M$382.1M$450.5M$483.7M$528.5M$474.6M$614.3M$576.0M$704.9M$837.3M$939.5M$1.04B
Inventory—$185.6M$200.8M$174.4M$145.8M$165.4M$246.9M$224.5M$268.3M$268.7M$349.6M$416.9M$457.0M$743.9M$998.0M$822.3M$927.7M$945.8M
Current assets—$985.3M$1.29B$1.36B$1.45B$1.56B$1.41B$1.42B$1.64B$1.07B$1.15B$1.52B$1.57B$1.93B$2.37B$2.36B$3.51B$4.32B
Property, plant and equipment—$387.1M$462.1M$434.4M$411.4M$434.3M$387.8M$384.3M$394.2M$386.6M$387.5M$417.3M$463.5M$498.2M$537.9M$548.0M$550.8M$581.8M
Goodwill—$198.6M$235.5M$256.2M$274.8M$289.3M$264.3M$1.06B$1.06B$1.07B$1.86B$1.89B$1.93B$1.94B$2.77B$2.84B$3.05B$2.91B
Acquired intangibles—$30.93M$47.91M$54.83M$49.64M$45.20M$47.14M$299.8M$261.8M$215.2M$522.0M$448.2M$392.6M$345.9M$552.3M$485.9M$464.9M$452.7M
Total assets—$1.63B$2.07B$2.14B$2.21B$2.36B$2.18B$3.26B$3.47B$3.06B$4.11B$4.59B$4.73B$5.10B$6.75B$6.87B$8.17B$8.97B
Accounts payable—$57.53M$55.19M$55.01M$60.69M$85.41M$81.11M$92.57M$92.76M$92.72M$115.7M$135.8M$138.0M$159.2M$150.8M$237.7M$278.2M$308.9M
Unearned revenue, current—$29.51M$45.13M$41.56M$44.95M$42.37M$36.10M$50.01M$51.92M$60.83M$88.67M$98.62M$109.6M$108.7M$138.1M$152.6M$166.0M$162.9M
Short-term borrowings———————$299.4M—$11.47M$11.99M$11.99M$12.00M$9.92M$9.90M$9.90M$9.90M$259.9M
Long-term debt · current portion—$121.7M$163.0K$52.00K$300.0M$18.00K————————————
Current liabilities—$312.7M$208.8M$252.9M$574.0M$269.6M$266.5M$638.0M$360.1M$511.2M$556.0M$602.8M$911.8M$689.3M$758.5M$910.7M$1.02B$1.40B
Long-term debt · non-current—$0.00$100.0M$250.8M$769.0K$300.8M$300.6M$873.3M$1.08B—————————
Operating lease liability———————————$123.1M$138.4M$142.3M$138.8M$166.7M$183.5M$166.6M
Total liabilities—$338.9M$338.2M$530.2M$600.2M$602.7M$594.5M$1.56B$1.51B$1.00B$2.04B$2.09B$1.84B$1.74B$2.62B$2.01B$2.21B$2.38B
Retained earnings—$884.9M$1.11B$1.37B$1.58B$1.78B$1.98B$2.16B$2.32B$2.43B$2.44B$2.83B$3.08B$3.61B$4.25B$4.99B$6.08B$7.26B
Shareholders' equity$1.12B$1.29B$1.73B$1.61B$1.61B$1.76B$1.59B$1.69B$1.96B$2.06B$2.07B$2.50B$2.89B$3.36B$4.13B$4.86B$5.97B$6.59B
Total liabilities and equity—$1.63B$2.07B$2.14B$2.21B$2.36B$2.18B$3.26B$3.47B$3.06B$4.11B$4.59B$4.73B$5.10B$6.75B$6.87B$8.17B$8.97B
Total debt—$121.7M$100.2M$250.8M$300.8M$300.8M$300.6M$1.17B$1.08B$281.5M$1.27B$1.30B$793.7M$917.5M$1.58B$873.9M$851.8M$825.9M
Net debt—−$367.1M−$635.1M−$558.7M−$575.3M−$604.9M−$416.7M$441.3M$256.7M$92.75M$1.12B$836.1M$498.4M$643.8M$1.35B$635.6M−$357.6M−$643.3M
Net working capital—$183.9M$348.3M$298.8M−$1.25M$380.9M$424.1M$50.30M$461.9M$365.8M$442.2M$457.5M$367.7M$968.5M$1.38B$1.21B$1.28B$1.46B
Shares outstanding · period end—151M152M142M142M140M140M141M142M143M144M145M146M146M147M147M146M144M

Quarterly

ResMed| balance sheet, quarterly
USDQ2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Cash and equivalents$210.2M$237.9M$238.4M$426.4M$521.9M$932.7M$1.21B$1.38B$1.42B$1.66B$1.47B$1.01B
Cash and short-term investments$210.2M$237.9M$238.4M$426.4M$521.9M$932.7M$1.21B$1.38B$1.42B$1.66B$1.47B$1.01B
Accounts receivable$729.7M$779.3M$837.3M$811.2M$859.9M$907.8M$939.5M$907.3M$985.6M$998.8M$1.04B$972.5M
Inventory$933.2M$829.5M$822.3M$918.0M$882.1M$862.6M$927.7M$945.8M$922.0M$911.9M$945.8M$1.02B
Current assets$2.38B$2.35B$2.36B$2.64B$2.84B$3.21B$3.51B$3.63B$3.82B$4.06B$4.32B$3.51B
Property, plant and equipment$551.7M$539.7M$548.0M$560.2M$520.2M$535.3M$550.8M$563.6M$564.3M$567.0M$581.8M$601.8M
Goodwill$2.86B$2.84B$2.84B$2.89B$2.81B$2.85B$3.05B$3.04B$3.04B$3.04B$2.91B$2.91B
Acquired intangibles$528.2M$501.0M$485.9M$478.6M$438.0M$430.1M$464.9M$447.1M$430.2M$425.2M$452.7M$442.7M
Total assets$6.91B$6.81B$6.87B$7.22B$7.14B$7.57B$8.17B$8.31B$8.50B$8.78B$8.97B$8.21B
Accounts payable$202.4M$177.4M$237.7M$249.3M$220.3M$222.6M$278.2M$266.8M$250.4M$273.3M$308.9M$320.7M
Unearned revenue, current$148.9M$150.8M$152.6M$157.2M$156.5M$160.4M$166.0M$167.8M$176.1M$179.3M$162.9M$171.6M
Short-term borrowings$9.90M$9.90M$9.90M$9.90M$9.91M$9.91M$9.90M$259.9M$259.9M$259.9M$259.9M$160.0M
Current liabilities$764.1M$773.0M$910.7M$904.1M$852.0M$940.5M$1.02B$1.26B$1.25B$1.35B$1.40B$1.32B
Operating lease liability——$166.7M———$183.5M———$166.6M—
Total liabilities$2.42B$2.18B$2.01B$2.03B$1.89B$2.02B$2.21B$2.19B$2.18B$2.29B$2.38B$2.26B
Retained earnings$4.54B$4.77B$4.99B$5.23B$5.49B$5.78B$6.08B$6.34B$6.65B$6.96B$7.26B$7.58B
Shareholders' equity$4.48B$4.63B$4.86B$5.20B$5.25B$5.55B$5.97B$6.12B$6.32B$6.49B$6.59B$5.95B
Total liabilities and equity$6.91B$6.81B$6.87B$7.22B$7.14B$7.57B$8.17B$8.31B$8.50B$8.78B$8.97B$8.21B
Total debt$1.39B$1.17B$873.9M$850.2M$839.7M$839.8M$851.8M$846.4M$847.7M$843.2M$825.9M$610.6M
Net debt$1.18B$929.5M$635.6M$423.9M$317.8M−$92.94M−$357.6M−$537.5M−$569.3M−$817.3M−$643.3M−$400.2M
Net working capital$1.40B$1.34B$1.21B$1.31B$1.46B$1.34B$1.28B$986.4M$1.15B$1.05B$1.46B$1.17B
Shares outstanding · period end147M147M147M147M147M147M146M146M146M145M144M141M

The main figures as JSON and plain text. See data and methodology.

RMD in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.